Welcome to our dedicated page for Elanco Animal Health Incorporated news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health Incorporated stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health, committed to innovating and delivering products and services to improve the health and wellness of both farm animals and pets. Established with nearly 70 years of heritage, Elanco operates in over 90 countries with a diverse portfolio of approximately 200 brands. Their core mission is encapsulated in their vision: 'Food and Companionship Enriching Life,' which they pursue through three primary avenues:
- Enhancing food security by improving the health and productivity of farm animals, thereby contributing to a safer, more affordable, and abundant food supply.
- Helping pets live longer, healthier lives through advanced veterinary products.
- Improving food safety standards globally.
Elanco’s dedication to animal health is reflected in their continuous innovation and quality systems, driven by a shared vision of enhancing life for animals and humans alike. This commitment is evident in their recent achievements and ongoing projects. For instance, Elanco's collaboration with Agtech company, Cattler, aims to provide data-driven solutions to cattle farmers, enhancing operational efficiency and productivity through services like Benchmark™ and Experior™.
Elanco's financial health is strong, with the company reporting consistent revenue growth and strategic investments aimed at future expansion. In their recent financial results, Elanco posted a 5% growth in the fourth quarter and strengthened their commercial infrastructure to support ongoing and future growth. They also announced the divestiture of their aqua business to streamline operations and focus on core areas, which is expected to reduce their debt leverage significantly by year-end.
Environmental sustainability is another critical focus for Elanco. Their recent partnership with Athian to create a livestock carbon insetting marketplace is a significant step towards reducing greenhouse gas emissions in the dairy and beef industries. Products like Bovaer®, which significantly reduce methane emissions from cattle, exemplify Elanco's commitment to sustainable farming practices.
Overall, Elanco continues to be at the forefront of animal health innovation, with substantial investments in R&D, strategic partnerships, and a clear commitment to sustainability and community health.
Elanco Animal Health (NYSE: ELAN) reported Q2 2024 results with revenue of $1,184 million, a 12% increase. The company saw a net loss of $50 million and adjusted net income of $147 million. Adjusted EBITDA stood at $275 million, 23.2% of revenue, while adjusted EPS was $0.30.
Elanco raised its full-year revenue guidance to $4,410-$4,460 million, reflecting 3-4% organic constant currency growth. The net income forecast is $314-$352 million, with adjusted EPS at $0.88-$0.96. The company completed the sale of its aqua business, reducing debt by $1.3 billion.
Key products like Experior, Adtab, and Credelio Plus contributed to growth. FDA approvals for Bovaer and the pending approval for Zenrelia are expected to boost future revenues. Pet Health revenue rose 12% to $579 million, while Farm Animal revenue increased 13% to $594 million. Gross profit was $689 million, 58.2% of revenue. Elanco projects $1.02-$1.05 billion in Q3 2024 revenue and $0.09-$0.14 in adjusted EPS.
Elanco Animal Health (NYSE: ELAN) has released its 2023 Environmental, Social and Governance (ESG) Report, highlighting progress in its four Healthy Purpose™ Pillars: Healthier Animals, Healthier People, Healthier Planet, and Healthier Enterprise. Key achievements include:
- Launched initiatives to combat canine parvovirus and expand pet care accessibility
- Introduced farm-level analytics for dairy producers
- Acquired NutriQuest® portfolio to offer antibiotic alternatives
- Achieved 12% renewable electricity use, progressing towards 100% by 2030
- Helped customers avoid 2.3 million metric tons of GHG emissions in 2023
- Contributed over 23,600 employee volunteer hours valued at $790,000
- Committed $3.7 million in charitable and community giving
The report also includes updated SASB and TCFD disclosures, reflecting Elanco's commitment to sustainability and its role as a competitive advantage in the animal health industry.
Elanco has introduced Bovaer® (3-NOP), a new feed ingredient for dairy cows that offers a dual benefit of environmental stewardship and financial rewards for farmers. This innovative solution allows dairy farmers to reduce greenhouse gas emissions while creating a new revenue stream through carbon credit sales.
The process is facilitated by Elanco's UpLook™ tool, which quantifies emissions reductions, and Athian, a livestock carbon inset marketplace for credit transactions. This development demonstrates that sustainability and profitability can coexist in modern dairy farming, providing a scalable approach to on-farm sustainability interventions.
Elanco Animal Health Incorporated (NYSE: ELAN) has announced the date for its second quarter 2024 financial results. The company will release its results on Thursday, August 8, 2024, followed by a conference call at 8:00 a.m. eastern time. This call will provide an opportunity for the investment community and media to gain further insights into the company's performance.
Investors, media, and the general public can access a live webcast of the conference call through a link that will be posted on Elanco's investor relations website. For those unable to attend the live event, a replay will be made available on the same website shortly after the call concludes.
Elanco has announced that its product Bovaer® (3-NOP) can significantly reduce methane emissions from dairy cows. Research indicates that feeding one tablespoon of Bovaer per lactating cow daily can cut methane emissions by approximately 30%, equating to around 1.2 metric tons of CO2e emissions annually. This reduction is comparable to removing 285,000 cars off the road for a year if applied to a million cows. The reduction in methane emissions can help mitigate climate warming by decreasing greenhouse gas levels.
Merck Animal Health, a division of Merck & Co., announced the completion of its acquisition of Elanco’s aqua business, strengthening its position in the aquaculture industry. This acquisition includes a diverse portfolio of vaccines, anti-parasitic treatments, water supplements, and nutrition products targeted at both warm and cold water species.
Notably, Merck now owns the CLYNAV® DNA-based vaccine, which protects Atlantic salmon against pancreas disease, and IMVIXA®, an anti-parasitic treatment for sea lice. This move leverages Merck’s capabilities to meet the growing global demand for quality protein and food safety, ensuring enhanced customer benefits and public health protection.
Elanco Animal Health (NYSE: ELAN) has completed the sale of its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3 billion in cash. Net proceeds of $1.05-$1.1 billion from this transaction are earmarked for debt reduction in the third quarter of 2024. This move allows Elanco to focus on high-value opportunities in pet health and livestock sustainability, while also enhancing financial flexibility. This transaction, combined with cash flow from operations, is expected to reduce Elanco's total debt by $1.3-$1.4 billion by the end of 2024. The company's net debt to adjusted EBITDA ratio is projected to improve from mid-4x in 2024 to high-3x to low-4x in 2025. Additional details will be provided in the second quarter earnings call in August.
Elanco Animal Health has announced major updates regarding FDA approval timelines for two key products: Zenrelia and Credelio Quattro. Zenrelia has completed all major technical sections and expects final approval by late Q3 2024, with a U.S. launch in Q4 2024. However, a safety warning on the label is anticipated to limit initial adoption by 25%. Zenrelia has already been approved in Brazil with further reviews pending in other markets.
Credelio Quattro has completed two of three major technical sections, with a response to an incomplete letter for the third section already submitted. Final approval is expected in Q4 2024, with a U.S. launch in Q1 2025. Elanco has increased its 2024 innovation sales guidance to $400-$450 million, driven by expected launches and strong existing product performance.
On June 26, 2024, Elanco announced that the Food and Drug Administration (FDA) has approved Bovaer, a feed additive that reduces methane emissions in dairy cows by 30%. This approval marks a significant advancement in sustainable agriculture, as methane is a potent greenhouse gas. Bovaer, which is already used in several countries, works by inhibiting a gut enzyme responsible for methane production. Studies confirm that it has no negative health impacts on cows or humans. This initiative is part of Elanco's broader efforts to provide environmentally friendly solutions in animal health.
Elanco Animal Health (NYSE: ELAN) has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 11-12, 2024. Jeff Simmons, the President and CEO, will engage in a fireside chat on June 11 at 2:40 p.m. ET. The event will be webcast live, and a replay will be accessible for 30 days on Elanco's investor website.
FAQ
What is the current stock price of Elanco Animal Health Incorporated (ELAN)?
What is the market cap of Elanco Animal Health Incorporated (ELAN)?
What is Elanco Animal Health's core mission?
In how many countries does Elanco operate?
What recent collaborations has Elanco engaged in?
What is the significance of Elanco's partnership with Athian?
What are some of Elanco's notable products?
How is Elanco addressing sustainability in animal farming?
What financial goals has Elanco set for 2024?
How does Elanco contribute to food safety?
What is Elanco's approach to innovation?
How does Elanco support the health and wellness of pets?
